Furthermore, post-trastuzumab tumors had a deletion of ERBB2 exon 16, resulting in a hyperphosphorylated ERBB2 isoform that is described to be resistant against ERBB2-targeted therapies in cancer models [35,36]. This evidence concerns the gene ERBB2 and cancer.